ArticleVirus genes2025
Development and application of a real-time fluorescent RAA assay for H9 subtype avian influenza viruses.
Article in Virus genes, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
The H9N2 subtype of avian influenza virus (AIV) is a critical pathogen responsible for avian infectious diseases, inducing respiratory symptoms in poultry and exhibiting high susceptibility to coinfections, which complicates clinical diagnosis. In this study, we designed specific primers and probes targeting the hemagglutinin (HA) gene of H9N2 AIV and developed a real-time fluorescent reverse transcription recombinase-aided isothermal amplification (RT-RAA) assay through systematic optimization of reaction components and conditions. The established method demonstrated exclusive reactivity with the H9N2 subtype, yielding negative results for all other tested viral pathogens, thereby showcasing high specificity. Analytical sensitivity testing revealed the capability to detect as low as 13.5 copies/μL of H9N2 viral RNA, indicating superior sensitivity. To further validate the practical application of this method, a total of 48 clinical samples, comprising oropharyngeal and cloacal swabs, were tested using the developed RT-RAA assay. The results revealed a positivity rate of 79%, reflecting strong diagnostic performance. This study presents a rapid RT-RAA assay characterized by high specificity and sensitivity, offering a robust technical platform for the immediate identification of H9N2 AIV and facilitating epidemiological surveillance in avian populations.
Indexed as
Identifiers
40498381What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.